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Abstract
Lassa virus is a linear, bisegmented, single-stranded RNA virus, which belong to the 
Arenaviridae family that causes viral hemorrhagic fever transmitted by rats. The virus is 
endemic in West African countries, which may be due to its zoonotic nature. Lassa virus 
infection occurs through contact with the vector Mastomys natalensis or infected humans 
and can lead to wide symptoms from a mild infection to Lassa fever and to a severe fatal 
viral hemorrhagic fever, which include delayed cellular immunity resulting to fulminant 
viremia. The virus replicates through a strategy known as the Ambisense, where two 
RNA strands code for genes in both the sense and antisense direction that is rapid and 
demonstrate temporal control in replication. Different diagnostic tests for the virus are 
available, which range from viral culture to serological and molecular diagnostic tests. 
There is an urgent need to develop drugs and vaccines against the virus because the 
World Health Organization (WHO) has identified Lassa virus as one of the viruses that 
is likely to cause a future epidemic, although a research is ongoing to evaluate Lassa 
virus vaccine immunogenicity in the CBA/J-ML29 mouse model. This chapter gives an 
overview on the structure, replication cycle, pathogenesis, and diagnosis of the virus.
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1. Introduction
Lassa virus (LASV) is first described in the 1950s [1] but not identified until 1969 in Jos, Nigeria 
[2, 3]. The virus causes Lassa fever that is hemorrhagic in nature, which is severe and fatal. It 
affects 2–3 million people annually [4, 5] and has been known to be endemic in Benin Republic 
in 2014, Ghana in 2011, Guinea, Liberia, and Mali in 2009, Sierra Leone, and Nigeria [3, 4, 6], 
but probably exists in other West African countries as well [4].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
It is a reemerging virus with a select agent, which requires Biosafety Level 4-equivalent con-
tainment [7]. It is endemic in West African countries including Sierra Leone, the Republic 
of Guinea, Nigeria, and Liberia, where cases of the infection is between 300,000 and 500,000 
yearly resulting in 5000 deaths annually [4, 8, 9]. About 80% infected with the virus are 
asymptomatic and 1 in 5 infection results in severe disease, where the virus affects several 
organs such as the liver, spleen, and kidneys [10]. The virus is harbored by the multimammate 
rats of the genus Mastomys and transmitted to Mans through primary aerosols of the rat’s 
urine, close contact with urine, feces, saliva, or ingestion of contaminated foods of the rat [11]. 
LASV is also spread through contaminated hospital equipment but interestingly, it cannot be 
contracted by humans to humans only via bodily fluids contacts [12]. Findings have reported 
the presence of the virus in seminal fluids up to 3 months after infection of the virus. Research 
to show that Lassa virus can be gotten via sexual intercourse has not been reported but there 
are speculations that LASV might possibly be used for bioterrorism, so it is now being studied 
at greater lengths [13, 14].
Due to the variability of the clinical course of the disease, detection of the disease in affected 
patients has been challenging. When presence of the virus is confirmed in a locality, quick 
isolation of infected patients, good infection prevention and control practices, and rigorous 
contact tracing can help halt epidemicity [15].
2. Aspect of Lassa virus structure
Lassa fever virus (LASV) is a member of the family Arenaviridae (“Arena” means “Sand” 
in Latin root) [16, 17]. The virus is single-stranded, bisegmented, ambisense RNA virus. 
Arenaviruses are classified as segmented negative-sense RNA (nsRNA) viruses and are 
phylogenetically closely related to other segmented nsRNA viruses belonging to the family 
Bunyaviridae and Orthomyxoviridae [9, 18]. The three virus families share similar characteristics 
of the intracellular replication cycle. It is round, oval, or pleomorphic, 110–130 nm in diameter, 
and has a protective envelop. LASV differ from 10 to 19 kilobases and contains two RNA spe-
cies, which are the big and small units [11, 19]. The two genes at different point do not cross 
exist in every unit [20, 21]. The genetic material that encodes nucleoprotein is 1710 nucleotides 
in length and the protein has 569 amino acids and that of glycoprotein is 1473 nucleotides long. 
The viral agent has four lineages, which differ in strain by 27% in respect to their nucleotides 
and 15% in respect to amino acids [22]. In the virus, the 3′ half of the genetic material has 
a negative polarity and the 5′ half is of a positive polarity that makes few virus proteins to 
encode in virus-complementary subgenomic mRNA species, while other viral proteins are 
encoded in virus-sense subgenomic mRNA sequences. The replication strategy (Ambisense) 
of the virus is somewhat seldom among viruses and thus distributed among groups of the 
Arenaviridae [15, 18].
The virus envelope is gotten when new particles bud off through the plasma membrane of 
the host cell and it carries club-shaped surface projections that are about 10 nm long [4, 19]. 
Sandy-appearing granules that resemble ribosomes are found within the unstructured interior 
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of new viruses. However, these RNAs do not seem to have a required function in virus replica-
tion cycle and new work by the Viral Hemorrhagic Fever Consortium [23] sheds suspicion on 
whether these sandy granules are indeed host ribosomes (Figure 1).
3. How Lassa virus replicates
Lassa virus adopts a replication strategy known as “Ambisense,” which is very rapid and dem-
onstrates the replication of temporal control [24]. The initial stage of transcription of mRNA 
Figure 1. The Virion and genome having the L and S segments [15, 17, 21, 23].
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copies of the negative sense gene, which makes sufficient deposition of virus proteins for the 
next stage of the replication process. Subsequently, L and NP proteins are translated from the 
mRNA. Copies of the viral complementary RNA (vcRNA) are made from the positive sense 
gene. Negative-sense progeny are produced by templates of RNA copies while mRNA is 
synthesized from it. The mRNAs produced from vcRNA are later translated to synthesize the 
Z and GP proteins. The temporal controls enhance the production of proteins spikes lastly, 
and therefore, delay the recognition by host immune system [25].
The virus enters into the host cell by means of the cell-surface receptor (alpha-dystroglycan 
alpha-DG), which is a versatile receptor for proteins of the extracellular matrix [26]. Receptor 
recognition is based on a specific sugar modification of alpha-DG by a group of glycosyl-
transferases known as the LARGE proteins. Specific variants of the genes encoding these 
proteins appear to be under positive selection in West Africa, where the virus is endemic 
[26]. Enveloped viruses makes use of clathrin-coated pits mostly to enter cells and bind to 
their receptors in a pH dependent way while Lymphocytic choriomeningitis and Lassa virus 
makes use of the endocytotic pathway independent of caveolin, clathrin, dynamin, and actin. 
The viruses are quickly delivered once within the cell to endosomes via vesicular trafficking 
albeit, which is extensively independent of the tiny GTPases Rab5 and Rab7. pH-dependent 
membrane binding happens on contact with the endosome, which is mediated by the envel-
oped glycoprotein, and at the acidic pH, the endosome fuses the lysosome protein LAMP1 
that yields in membrane bind and endosome escape [19].
NP is the most dominant viral protein in virions and infected cells, which consists the main 
structural component of the viral ribonucleoprotein (RNP), which plays an important role 
in the RNA synthesis of the virus. Subsequently, the function required to assist replication 
of the virus, at least two viral proteins (NP and Z), have been proposed to modulate the cell 
response of the host to infection. Experimental data has showed that NP has a role in virus-
induced inhibition of type I IFN signaling [27]. This role has been mapped to the C-terminal 
domain of NP with a folding that camouflages the DEDDH family of 3′-5′ exoribonucleases. 
The little RING finger protein Z is the arenavirus counterpart of the matrix (M) protein of 
other negative sense RNA viruses. The Z protein of lymphocytic choriomeningitis virus 
(LCMV) interacts with the promyelocytic leukemia (PML) protein as well as the eukaryotic 
translation initiation factor 4E (eIF4E) in infected cells and has been observed to function 
in the noncytopathic nature of LCMV infection and repression of cap-dependent translation 
[22, 28, 29]. Functional assays reported the exonuclease activity of LASV NP that has been 
proposed as important for its type I IFN counteracting functions [29].
The replication cycle of Lassa virus is similar to the Old World arenaviruses. It was reported that 
virus internalization is limited upon cholesterol depletion. Dystroglycan, which is later cleaved 
into alpha-dystroglycan and beta-dystroglycan is initially expressed in most cells to mature 
tissues, which provides molecular bridge between the actin-based cytoskeleton and extracel-
lular matrix (ECM) [26, 30]. After the viral agent enters the cell by alpha-dystroglycan-mediated 
endocytosis, low-pH domain enhances pH-dependent membrane bind and releases ribonucleo-
protein of the virus (RNP) complex into the cytoplasm. The enzymatic machinery for RNA 
synthesis in arenaviruses is housed within a single L polymerase protein. This 250–450 kDa 
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protein utilizes viral RNA templates that consist of genomic RNA encapsidated by the viral 
nucleocapsid protein NP and comprises viral ribonucleoprotein [21, 30]. L polymerase of arena-
viruses contains the SDD motif feature of all RNA-dependent RNA polymerases (RdRp) [10]. 
When infected, the viral agent RNP is inserted into the cytoplasm of the host cell, the L poly-
merase associated with the viral RNP starts transcription from the genome promoter located at 
the 3′-end of each genomic RNA segment, L and S. The 5′ and 3′ terminal 19 nt viral promoter 
regions of both RNA segments required for the recognition and binding by the viral polymerase 
exhibit a high degree of conservation among the arenaviruses. The genome segments have a 
high complementary 5′- and 3′-ends (19 nt) have been predicted to form panhandle structures 
[10, 11]. Transcription stops at the distal side of the stem-loop (SL) structure within the interge-
nomic region (IGR). The L polymerase adopts a replicase mode and moves across the IGR to 
create a full-length complementary antigenomic RNA (agRNA) that serves as a template for 
mRNAs synthesis of viral genes encoded in genomic orientation, GPC and Z, from the S and L 
segments, respectively, and for the synthesis of full-length genomic RNA (gRNA) [13, 18]. This 
SL structure has been discovered to stabilize the 3′-termini of the viral mRNAs [10]. The primary 
transcription leads in the mRNA synthesis of viral genes, which is encoded in antigenomic 
orientation, NP and L polymerase, from the S and L segments, respectively. The viral agent uses 
a cap snatching strategy to acquire the cap structures of cellular mRNAs. Cap snatching is facili-
tated by the endonuclease activity of the L polymerase that is co-factored by the cap binding 
activity of NP. Therefore, LASV synthesizes capped nonpolyadenylated mRNAs. Both gRNA 
and agRNA of the viral agent contain a nontemplate G residue at their 5′-ends. The proposed 
“prime and realign” mechanism includes the production of a pppGPCOH dinucleotide primer from the CG nucleotides at positions +2 and +3 of the 3′-end genome promoter sequence, that is, 
then realigned such that its 3′-terminal C
OH
 is opposite the genome 3′-terminal G residue, and 
the realigned pppGPCOH then acts as a primer for a complementary RNA strand production. The matrix protein Z is not part of the viral genome transcription and replication but shows a 
dose-dependent inhibitory effect on viral RNA production. This inhibitory effect of Z has been 
proposed for Old and New World arenaviruses [27].
4. An aspect of Lassa virus pathogenicity
The Lassa virus is well-known to cause Lassa fever [31]. Its symptoms include flu-like illness 
characterized by fever, general body weakness, cough, tonsillitis, headache, and gastrointes-
tinal disorders. Hemorrhagic manifestations are other features of Lassa fever, which include 
vascular permeability [10].
The virus pathogenesis is still unclear, but it has been shown that the virus chiefly target 
the antigen-presenting cells (mainly dendritic cells) and endothelial cells [32]. Lassa virus 
infects most tissues in the human body when gained entry. It starts with the mucosa, intes-
tine, lungs, and urinary system, and then moves to the vascular system. There are findings 
that the viral agent can prevent a host’s innate immune system by NP activity [33]. Usually, 
when a microbe penetrates a host, the innate defense system detects the pathogen-associated 
molecular patterns (PAMPs) and aggravates the response of the immune system. One of the 
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mechanisms identifies double-stranded RNA that is only produced by negative-sense viral 
agents [34]. In the cytoplasm, dsRNA receptors, such as melanoma differentiation-associated 
gene 5 (MDA-5) and retinoic acid-inducible gene I (RIG-I), detects dsRNAs and facilitates 
signaling pathways that results in the translocation of interferon regulatory factor 3 (IRF-3) 
and other transcription factors to the nuclear material [9]. Translocated transcription fac-
tors enhance expression of interferons 𝛂 and 𝛃, and secreted interferons facilitate antiviral 
responses including adaptive immunity. NP encoded in the viral agent is important in the 
replication and transcription of the virus, but it also stops host innate IFN response by inhibit-
ing translocation of IRF-3. NP of the virus is reported to have an exonuclease activity to only 
dsRNAs [12]. Double-stranded RNA exonuclease activity of the NP leads to counteract IFN 
responses by digesting the PAMP that leads to the evasion of host immune responses.
The recent understanding of the pathogenesis of the viral fever does not involve the chain 
of functions that take place during development of the disease state and leads to mortality 
of severed ill patients [35]. The high death and truly dramatic course of the disease state, 
the pathological findings do not give the bench that would explain the mechanism of dis-
ease progression and the cause of mortality by the viral agent [5, 8]. Development of the 
cellular immune response failure, which would control dissemination of LASV is indicated 
by high serum titers of the virus, together with dispersed replication in tissues and lack of 
neutralizing antibodies that could lead to the fatal Lassa fever development [6, 36]. Patients 
check physically after fever onset usually depicts facial oedema, bilateral conjunctival hemor-
rhages, purulent pharyngitis, and abdominal disorders [5]. Pathological changes physically 
may include pulmonary oedema, ascites, pleural effusions, and hemorrhagic signs in the 
gastrointestinal mucosa while examination under the microscope reveals splenic necrosis, 
hepatocellular necrosis, adrenocortical necrosis and apoptosis, mild mononuclear interstitial 
myocarditis without myocardial fiber necrosis, alveolar oedema with capillary blockage and 
mild interstitial pneumonitis, lymph nodal sinus histiocytosis with mitoses, gastrointestinal 
mucosal petechiae, renal tubular injury, lymph nodal sinus histiocytosis with mitoses, and 
interstitial nephri. More often, lesions of Lassa fever in man happen in the hepatic cells [5, 8]. 
There are four major characteristic hepatitis of LASV, which is derived:
i. Focal cytoplasmic degeneration of hepatocytes related to phagocytosed apoptotic fragments.
ii. Distribution of multifocal hepatocellular necrosis randomly.
iii. Monocytic reaction to necrotic hepatocytes.
iv. Hepatocellular mitoses.
The physical impacts do not happen uniformly in all cases, rather in some instances can be 
observed simultaneously.
The virus fever is not associated with coagulation dysfunction, for example, decrease in the 
coagulation factors and disseminated intravascular coagulation (DIC) have been revealed 
in infected subjects. More so, moderate thrombocytopenia with importantly damaged func-
tionality of thrombocytes is reported in severe Lassa fever subjects [7, 36]. One significant 
mechanism involved in the pathogenesis of Lassa fever is infection-triggered induction of 
uncontrolled cytokine expression, which looks like what is seen in sepsis [9]. In this subject 
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that died from hemorrhagic shock and multi-organ failure, the proinflammatory cytokines, 
tumor necrosis factor α (TNF-α), and interferon γ (IFN-γ) rises to extremely high level just 
before death. In a related study, no increase of both cytokine levels was reported in the 
checked fatal cases of the virus fever, and it is suggestive that the levels of IFN-γ and TNF-α 
are either elevated only in a fraction of patients or during a limited period that would involve 
frequent sampling for assay [12, 34].
Virus-induced immunosuppression may be involved in a severe Lassa fever pathogenesis where 
the LASV infection fails to trigger macrophages (MP) and monocyte-derived dendritic cells (DC) 
of human. Human-infected DC with the naturally nonpathogenic mopeia virus, induces stronger 
CD4 and CD8 T-cell responses when compared with those infected with LASV [5, 8]. Infected DC 
fail to secrete proinflammatory cytokines, do not upregulate costimulatory molecules, such as 
CD40, CD80, and CD86, and poorly induce proliferation of T cells. Downregulation of immune 
responses due to infection by LASV has been depicted in vitro, and it is also in consonance with 
findings of clinical reports demonstrating that the virus fever fatal outcome relates with low 
levels interleukin (IL) 8 and IFN inducible protein 10 (IP-10) in the system [14].
5. Aspect of Lassa virus diagnosis
Different diagnostic tests in the laboratory are carried out in order to check the presence of 
an infection and assess its course and complications. The unavailability of lab tests can com-
promise diagnosis confidence. The most disturbing factor is the presence of febrile illnesses 
in Africa that mimics the Lassa fever, such as typhoid fever especially for manifestations of 
nonspecific Lassa fever [31]. In illness with abdominal pain, in countries where the virus is 
epidemic, Lassa fever may be misdiagnosed as intussusception and appendicitis that leads 
to delay in treatments with the antiviral drug (ribavirin) [37]. In West Africa, where the virus 
is most prevalent, it is difficult for laboratory scientists to diagnose due to the absence of the 
right equipment to perform the tests [4].
The Federal Drug Administration (FDA) has not approved any widely validated laboratory 
test for the virus, but there are diagnostic tests, which have been able to provide definitive evi-
dence of the presence of the virus [4, 14]. These tests include viral cultures, polymerase chain 
reaction (PCR) where the virus can be uncovered using reverse transcription PCR after first 
reverse transcribing the RNA of the virus into DNA, Enzyme Linked Immunosorbent Assay 
(ELISA) test, immunofluorescence test, and plaque neutralization. But, immunofluorescence 
tests give less definitive presence evidence of the viral presence. Other laboratory reports in the 
virus fever include thrombocytopenia, lymphopenia, and elevated aspartate aminotransferase 
levels in the blood. The viral agent can occasionally be present in cerebrospinal fluid [38, 39].
The following diagnostic methods are briefly discussed below.
5.1. Viral culturing
Viral isolation in cell culture remains the “gold standard” for the diagnosis of Lassa fever 
given the challenges in diagnosing the virus due to mutations [38], although RT-PCR and 
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immunoassays are commonly used assays for a clinically actionable diagnosis in recent time 
[7, 40]. Viral culturing is carried out by the inoculation of suspected samples containing the 
virus in Vero E6 cells in incubator at 37°C. A positive result may yield a cell cytopathic effect 
(CPE) [41], while, a second method of detection, such as viral antigen detection, RT-PCR, or 
electron microscopy, should be used as confirmatory for the presence of the virus. There is 
always viremia presence at the time of presentation to medical care and reduces after 6 days 
of illness in subjects, who survived the infection and there may be persistence presence until 
death in fatal cases [42]. The viral agent can also be cultured from throat swabs, blood, urine, 
and cerebrospinal fluid specimens from subjects [4]. The detection of virus in urine and throat 
swabs can be inconsistent in subjects with serum viremia. Positivity of the viral culture may 
exists in organ specimens such as spleen, liver, lung, heart, kidney, and placenta at post mor-
tem in fatal infections cases [4].
Culturing of viruses allows for the identification, which is genetically independent of vari-
abilities between types and further typing of the viral agent, if desired is achieved [38]. This 
technique also guarantee the quantification of viremia that might provide further viral typing 
data, as viremia with 103 50% tissue culture infective doses (TCID50)/ml has a fatality odds ratio of 3.7 as regards to viremia with less than 103 TCID50/ml. The method is neither fast, taking at least several days to yield results, and it is not widely available due to the need for 
BSL-4 precautions to handle live viral samples that limits its utility for the early diagnosis of 
the viral infection [31].
5.2. Rapid immunogenic tests
Rapid immunogenic tests are attractive alternatives to the technical requirements and 
high specificity of the PCR methods especially in LASV endemic areas [14, 37]. The anti-
body/antigen binding is usually less specific than primer/probe hybridization, leaving for 
greater flexibility in identifying diverse viral agents. Detection of antigens relies on specific 
antibodies usage against Lassa virus components to detect viral antigens in blood samples 
[14]. Nonspecific Lassa virus antigens with polyclonal antibodies are detected with initial 
assays, whereas more current ELISAs target the Lassa virus nucleoprotein antigen [31, 38]. 
A diagnosis based on the detection of the relatively conserved Lassa nucleoprotein antigen 
could reduce the differences in test efficacy between genetically diverse virus types and com-
parison to DNA-based techniques [43]. Antigenemia-increased levels have been identified in 
fatal cases of the fever when compared with nonfatal cases. The short time of antigenemia 
enhances the detection of the virus antigen more specific to acute infection with the virus 
when compared to detection with antibody tests. The antigen of the virus nucleoprotein can 
be detected in subjects with the virus in the first week of illness and wanes during the second 
week in temporal association with the increase in detectable immunoglobulins [42]. Antigen 
detection tests could identify Lassa fever earlier during illness than antibody tests, as antibod-
ies often may not be detectable until the second week of illness [43, 44]. The virus antigen lev-
els might become undetectable despite viremia persistence. It should be noted that, negative 
antigen test during an acute illness does not mean that the patient is free from the fever [44].
A lot of IgM and antigen capture ELISA methods have been invented with inactivated viral 
agent; but the protocol is restricted to BSL-4 capable machine [41]. Recombinant antigens 
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usage allows improved access and assay development. A lateral passage test for the virus 
nucleoprotein (ReLASV) is another type of diagnostic test, which may be used for point-of-
care diagnosis [45]. Following initial development and testing efforts, this test received the CE 
mark in 2013, although approval by the US FDA has not been granted for the test. According 
to the product insert, the assay generates results in 15–25 minutes and has 85 and 99% sensi-
tivity and specificity, respectively using confirmed Lassa virus-positive blood specimens [4].
In real sense, a diagnostic test would not only identify Lassa virus infection but would also 
check for other pathogens with similar clinical symptoms endemic in West Africa at the 
same time [39]. A transitioning Lassa and Ebola virus antigen- and IgM-based ELISAs onto a 
MAGPIX system has been described that uses individually labeled magnetic beads to identify 
multiple targets in a single test. This test has lower limits of detection for Lassa virus nucleo-
protein and IgM than conventional ELISAs. Further development of multiplex MAGPIX 
assays, including testing for Lassa virus antigen and common endemic infections such as 
malarial infection, will assist with the diagnosis and clinical management of suspected cases 
of Lassa fever, especially in cases of coinfection with other pathogens where multiple thera-
peutic modalities may be indicated [38]. Patients on medical care dalliance following onset of 
the disease could affect negatively on the virus identification in a nucleoprotein detection test, 
and detection by viral-specific IgM might be more appropriate and reliable [37, 42]. IgG of 
the virus levels may increase later than IgM levels, with a mean time to detection of 25.6 days 
after symptom onset, although positive IgG titers have occasionally been detected presence 
in subjects with acute fever within the first few days of sickness onset [38]. IgM of the virus 
usually becomes noticeable and detectable in the second week of infections onset, although 
it could be detectable within 4 days of onset of illness in some subjects. Lack of an antibody 
response has been found in some fatal cases of Lassa fever.
5.3. Polymerase chain reaction (PCR) methods
Real-time RT-PCR is a commonly used diagnostic technique for infectious agents due to the 
high specificity and sensitivity and has become a gold standard clinically for Lassa fever identi-
fication [37, 46, 47]. Automated coupled specimen processing and 96-well plate thermocyclers, 
large samples can be evaluated fast and cheaply. The methods could detect viral agent for early 
illness and a longer time when compared to culturing of virus and might be carried out on 
samples that are inactivated chemically [4, 48]. Cycle threshold figures usage with quantitative 
rt-PCR can help with estimates of viremia using the right positive-control equipment for gen-
eration of standard curve [49]. Based on the virus strain and primers used, the 95% probability 
limit of detection estimates with RT-PCR vary from 1237 to 4290 RNA copies/ml [49]. With 
highly diverse viral agent such as Lassa virus, molecular diversity can be a problem for such 
assay, as even a single nucleotide variant in one of the primers can have a significant negative 
effect on the sensitivity of the assay depending on the location of the nucleotide variant [50–52].
The availability of additional sample testing and sequencing data has made mismatches identi-
fied using established assays, necessitating assay redesign to enhance performance. Multiplex 
panels to simultaneously detect a multitude of viruses that could produce hemorrhagic fever 
syndromes, including Lassa and Ebola viruses, using RT-PCR alone or in synergy with either 
enzyme hybridization or ligase detection reactions have also been produced [53, 54].




The Lassa virus is one of several viruses that are likely to cause a future epidemic as reported 
by World Health Organization [4, 43, 44]. The appropriate diagnosis of Lassa fever will 
likely involve a combination of a clinically compatible observation along with serological 
and molecular diagnostic assays [5]. There is a need for urgent research and development of 
new diagnostic tests, vaccines, and drugs [7]. Future directions of research for diagnostics in 
the viral infection are improvement of assays to enhance detection of different viral strains 
genetically, validation of assays to depict variations in viral lineages and regions, creation 
of point-of-care detection and field validation, and expansion of multiplex assays content 
to differentiate the virus fever from other fevers with alike clinical features. Research on the 
virus vaccine immunogenicity in the CBA/J-ML29 mouse subjects is ongoing. Until now, no 
licensed vaccine for humans against the virus exists [45].
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